Evidence map›Paper›PMID 36692832›Full record

ArticleJournal of neuro-oncology2023

Long-term outcomes of fractionated proton beam therapy for benign or radiographic intracranial meningioma.

Adam L Holtzman, Gabriella E Glassman, Roi Dagan, Dinesh Rao, Peter J Fiester, Daryoush Tavanaieour, Christopher G Morris, Daniel J Indelicato, William M Mendenhall

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adam L HoltzmanDepartment of Radiation Oncology, University of Florida College of Medicine, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA. aholtzman@floridaproton.org.ORCID http://orcid.org/0000-0002-1412-7155
Gabriella E GlassmanDepartment of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
Roi DaganDepartment of Radiation Oncology, University of Florida College of Medicine, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA.
Dinesh RaoDepartment of Radiology, University of Florida College of Medicine Jacksonville, Jacksonville, FL, USA.
Peter J FiesterDepartment of Radiology, University of Florida College of Medicine Jacksonville, Jacksonville, FL, USA.
Daryoush TavanaieourDepartment of Neurosurgery, University of Florida College of Medicine Jacksonville, Jacksonville, FL, USA.
Christopher G MorrisDepartment of Radiation Oncology, University of Florida College of Medicine, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA.
Daniel J IndelicatoDepartment of Radiation Oncology, University of Florida College of Medicine, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA.
William M MendenhallDepartment of Radiation Oncology, University of Florida College of Medicine, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBenign intracranial meningioma is one of the most common primary brain neoplasms. Proton therapy has been increasingly utilized for nonoperative management of this neoplasm, yet few long-term outcomes studies exist.

methodsThe medical records of a total of 59 patients with 64 lesions were reviewed under a prospective outcomes tracking protocol for histologically proven or radiographically benign meningioma. The patients were treated with proton therapy at the University of Florida Proton Therapy Institute between 2007 and 2019 and given a median dose of 50.4 GyRBE at 1.8 GyRBE (relative biological effectiveness) (range 48.6-61.2 GyRBE) in once-daily treatments.

resultsWith a median clinical and imaging follow-up of 6.3 and 4.7 years, the rates of 5-year actuarial local progression and cumulative incidence of grade 3 or greater toxicity were 6% (95% confidence interval [CI] 1%-14%), and 2% (95% CI < 1%-15%), respectively. Two patients experienced local progression after 5 years. The 5-year actuarial overall survival rate was 87% (95% CI 74-94%).

conclusionFractionated PBT up to 50.4 GyRBE is a safe and highly effective therapy for treating benign intracranial meningioma.

Indexed as

Meningeal NeoplasmsMeningiomaProton TherapyHumansProspective StudiesBenignCentral nervous systemMeningiomaParticle therapyRadiation therapy

Identifiers

PMID36692832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.